IntraOp Medical Corporation (OTCBB: IOPM), a provider of innovative technology solutions for the treatment and eradication of cancer, today announced it has delivered a Mobetron® system to the Cancer Institute & Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing, China. Mobetron is a proprietary, mobile electron-beam instrument designed for Intraoperative Electron Radiation Therapy (IOERT), the direct application of radiation to a tumor while a patient is undergoing cancer surgery. The Mobetron will form an integral component in the Chinese Government’s new initiative to combat lung cancer as well as be used to provide IOERT treatment for a variety of other cancers.
Dr. Donald A. Goer, president and CEO of IntraOp Medical Corporation, said, “Lung cancer is a major worldwide health problem and one of China’s fastest growing diseases. By establishing a world-class research and treatment center for lung cancer at the CAMS Cancer Hospital, the Chinese Ministry of Heath is demonstrating its commitment to making effective treatment viable for all patients. In addition, installing an IOERT system at the Beijing facility will broaden clinical research efforts in the United States as well as Europe and refine our worldwide understanding of IOERT’s proper role in the treatment of lung and other cancers.”
“The successful integration of Mobetron into our cancer program is a momentous event since we have over 8,000 cases for cancer operation treatment each year,” emphasized Professor Zhao Ping, Dean of the Cancer Institute & Hospital, Chinese Academy of Medical Sciences. “As the first operating room based IOERT unit in of all of China, we now have the means to use IOERT effectively and efficiently. Having Mobetron and IOERT in the operating room, we believe, is a significant start to producing better outcomes across our country for patients with this devastating disease.”
Mr. Hu Zhongjin, CEO of Huilong Group, IntraOp’s partner in China, said, “The Cancer Institute & Hospital is a prestigious academic research institution, internationally recognized for its cancer research and treatment programs. We believe this installation of Mobetron will expedite the use of IOERT in China and help expand clinical research efforts worldwide”.
The Lung Cancer Initiative was officially inaugurated on October 20, 2006, by China’s Vice-Minister of Health, Dr. Huang Jiefu, himself a surgeon, at a special symposium. Prominent lung cancer researchers and practitioners throughout China came together to share their research, to discuss the status of lung cancer both in China and the rest of the world, and to suggest promising avenues of research for the treatment of this disease.
About CAMS Cancer Hospital
Cancer Institute & Hospital, Chinese Academy of Medical Sciences, http://www.cicams.ac.cn/web/index.aspx, is the teaching, research and treatment hospital of the Beijing University Medical School, focusing on the prevention, treatment and rehabilitation of cancer patients. With more than 1,000 beds, the institution treats 8,000 patients per year. In addition to a modern radiotherapy department, the center boasts one of the most advanced tumor molecular biology laboratories in the world.
About IntraOp
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively — for all cancer patients. The company’s flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.
For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company’s products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.
Comments